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ABSTRACT
Understanding human cancer increasingly relies on insight gained from subtype 
specific comparisons between malignant and non-malignant cells. The most frequent 
subtype in breast cancer is the luminal. By far the most frequently used model for 
luminal breast cancer is the iconic estrogen receptor-positive (ERpos) MCF7 cell line. 
However, luminal specific comparisons have suffered from the lack of a relevant 
non-malignant counterpart. Our previous work has shown that transforming growth 
factor-β receptor (TGFβR) inhibition suffices to propagate prospectively isolated 
ERpos human breast luminal cells from reduction mammoplasties (HBEC). Here we 
demonstrate that transduction of these cells with hTERT/shp16 renders them immortal 
while remaining true to the luminal lineage including expression of functional ER 
(iHBECERpos). Under identical culture conditions a major difference between MCF7 
and normal-derived cells is the dependence of the latter on TGFβR inhibition for ER 
expression. In a breast fibroblast co-culture model we further show that whereas MCF7 
proliferate concurrently with ER expression, iHBECERpos form correctly polarized acini, 
and segregate into proliferating and ER expressing cells. We propose that iHBECERpos 
may serve to shed light on hitherto unappreciated differences in ER regulation and 
function between normal breast and breast cancer.
INTRODUCTION
Although human breast cancer was one of the first 
cancer forms to receive precision medicine based on 
molecular ER profiling, a number of questions pertinent to 
the insurgence and treatment failure of this disease remain 
largely unanswered. One of the most puzzling discoveries 
is the apparent master switch between quiescence in 
normal ERpos breast epithelial cells and proliferation 
in ERpos breast cancer cells with concurrent increasing 
failure to down-regulate ER [1, 2]. Likewise, the opposite 
scenario, i.e. the evolution of a complete receptor-negative 
breast cancer leading to de novo resistance to anti-estrogen 
treatment also poses a considerable challenge and remains 
poorly understood [3].
Our current understanding of the regulation of 
ER expression and the mechanism of action of estrogen 
in human breast cancer almost exclusively relies on 
experiments with one cell line, MCF7, established from 
a metastatic lesion more than four decades ago [4]. 
Accordingly, MCF7 has received more than twenty five 
thousand hits in PubMed (for review see [5]). Other than 
being a widely used model for ERpos breast cancer MCF7 
also represents luminal B breast cancer which aside from 
being very proliferative is characterized by exhibiting a 
phenotype reminiscent of the luminal lineage in the normal 
human breast [6, 7]. This lineage is characterized by an 
almost universal expression of the simple cytokeratins K7, 
K8, K18, and K19 and the concomitant overall absence 
of basal cytokeratins K5, K6, K14, and K17 (for review 
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see [8]). It is also characterized by expression of a highly 
glycosylated sialomucin encoded by MUC1 [9, 10].
Non-malignant equivalents to breast cancer subtypes 
in general have proven to be extremely valuable in 
understanding breast cancer evolution and in the search 
for precision drug targets [11–15]. However, when it 
comes to the by far most frequent luminal cancer, the 
ERpos, a non-malignant equivalent does not exist [7, 16]. 
Spontaneously immortalized cell lines such as HMT3522 
[17] and MCF10A [18] are better counterparts for basal-
like breast cancer and they are negative for keratin K19 
and ER [19], and telomerase immortalized human breast 
epithelial cells continue to express basal keratin K14 and 
p63 [13]. Likewise, while modifying p53 and Rb by SV40 
or E6/E7 transfection leads to established cell lines with 
luminal characteristics, functional ER expression at the 
protein level has not been accomplished [20, 21].
Recently, we isolated and cultured human breast 
ERpos cells which remained responsive to estrogen and 
showed that inhibition of TGFβR signaling was key to 
release of ERpos cells from growth restraint [22]. Extended 
culture was obtained by transduction with hTERT/shp16. 
Here we describe iHBECERpos which are remarkably similar 
in phenotype to MCF7 by critical lineage markers and 
ER expression. We compare the functional properties of 
iHBECERpos and MCF7 under identical culture conditions 
which offers a unique opportunity to dissect at the 
molecular level the aberrations associated with malignant 
transformation of the most frequent breast cancer subtype.
RESULTS
A luminal ERpos cell line, iHBECERpos, 
is established from hTERT/shp16 
transduction of normal breast ERpos cells
Using a high titer sequential retroviral transduction 
protocol we transduced reduction mammoplasty-derived, 
prospectively sorted CD166high/CD117low luminal cells 
with a combination of hTERT and shp16 [22] and 
monitored proliferation of these cells over a few months. 
iHBECERpos was established which, unlike the non-
transduced control, could be expanded continuously 
without undergoing crisis. Since our aim was to establish 
a common ground for comparison between iHBECERpos 
and MCF7, we tested the ability of MCF7 to grow under 
similar conditions. TGFβR2i did, however, not support 
growth of MCF7 (Figure 1). Therefore, we tested which 
growth factors in TGFβR2i should be omitted to allow 
growth, and identified cholera toxin and hydrocortisone 
as inhibiting factors. As we had previously observed 
that substitution of epidermal growth factor with 
amphiregulin supported ER expression and function 
in normal cells, this modification was included in the 
modified medium, referred to as TGFβR2i-1. MCF7 was 
easily adapted to grow under these conditions (Figure 1). 
Switching back to TGFβR2i again inhibited growth of 
MCF7, underscoring that MCF7 indeed cannot grow in 
TGFβR2i (Figure 1). iHBECERpos cells easily adapted to 
TGFβR2i-1, and thus, MCF7 cells and iHBECERpos cells 
both grew well on TGFβR2i-1 (Figure 1). This opened 
for direct comparisons under identical conditions. Normal 
luminal epithelium and luminal breast cancer have been 
successfully characterized by expression of keratin K8, 
K19 and MUC1 and lack of expression of keratin K14 and 
p63. We found that iHBECERpos essentially aligned with 
these criteria and thus critically resembled MCF7 cells by 
lineage (Figure 2). A more accurate position of iHBECERpos 
in the breast hierarchy was obtained by use of Lim et al.’s 
gene expression data [23]. Comparison of the RNA-Seq 
expression profile of iHBECERpos with the available top 
twenty highest expressed genes for each of the epithelial 
subpopulations in Lim et al.’s differentiation hierarchy - 
ranging from mammary stem cells/bipotent progenitors 
(MaSC/BiPs) through luminal progenitors (pLs) to mature 
luminal cells (mLs) - revealed that iHBECERpos cells most 
likely are equivalent to luminal progenitors (Figure 3).
iHBECERpos are able to recapitulate normal-like 
behavior in three-dimensional rBM
To establish functional evidence for the non-
malignant nature of iHBECERpos, we employed our 
original reconstituted basement membrane (rBM) assay 
[24]. Whereas both iHBECERpos and MCF7 cells formed 
similar epitheloid sheets in monolayer culture, in three-
dimensional rBM, many iHBECERpos cells remained as 
single cells and eventually died, but some were capable 
of forming clonal acinus-like spheres (33.2% +/- 0.9) with 
a central lumen (Figure 4). By comparison MCF7 cells 
grew into larger clusters of cells (Figure 4). Staining of the 
sectioned rBM gels showed that acinus-like iHBECERpos 
cells were luminally restricted and correctly polarized 
with apical expression of MUC1 (Figure 4), while MCF7 
cells remained unpolarized (Figure 4). ER expression was 
lost in both lines by exposure to rBM. Upon this initial 
characterization of the two cell lines, we focused our 
subsequent analyses on comparing iHBECERpos with MCF7 
cells with respect to their response to the principal female 
sex hormone, estradiol.
ER expression in iHBECERpos is subject to 
TGFβR regulation
To assess the fundamental precondition for estrogen 
action we first stained for canonical ERα. We found distinct 
nuclear ER staining in about half of the iHBECERpos cells 
and in the majority of MCF7 cells (Figure 5A and 5C). 
To ensure that the observed iHBECERpos phenotype reflects 
that of non-immortalized cells under similar conditions, 
we further verified that EpCAMhigh/CD271low/CD166high/
CD117low cells in early culture could be expanded and 
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retained ER expression in TGFβR2i-1. We have previously 
shown that ER expression in normal breast epithelial cells 
is dependent on continuous TGFβR inhibition [22], and 
we therefore addressed whether TGFβR inhibitors affected 
SMAD signaling and ER expression in MCF7 in a similar 
way. Within six days of omission of TGFβR inhibitors, 
iHBECERpos upregulated pSMAD2 and downregulated 
ER completely (from 44 +/- 5% ER-positive cells with 
inhibitors to 0% upon omission; Figure 5B), while ER 
expression in MCF7 cells was unaffected (87 +/- 4 % 
ER-positive cells with inhibitors and 90 +/- 7 % without 
inhibitors, n=3 x 100 cells, not significant by Student´s 
T-test). Apparently, however, the lack of ER regulation in 
MCF7 was not due to insensitivity to TGFβR inhibition, 
since pSMAD2, albeit to a relatively modest level, was 
induced upon omission of TGFβR inhibitors (Figure 
5B). The results suggest that in MCF7 ER expression is 
independent of TGFβR signaling.
Estrogen-regulated genes differ between 
iHBECERpos and MCF7
The presence of elements of a functional ER 
signaling pathway in iHBECERpos and MCF7 cell lines was 
further demonstrated by staining for ER and progesterone 
receptor (PR) in response to estrogen (Figure 5C). 
While both lines down-regulated ER expression upon 
stimulation with estrogen, iHBECERpos significantly 
upregulated PR protein expression (Figure 5C). We 
next assessed the growth response to estrogen with or 
without the estrogen receptor antagonist, ICI-182,780 
(Figure 5D). While estrogen-induced proliferation was 
completely abrogated by ICI-182,780 in iHBECERpos, 
MCF7 did not exhibit a proliferative response in 
TGFβR2i-1 (Figure 5D). That MCF7 sublines may 
exhibit different growth responses to estrogen is not 
unprecedented. Here, MCF7 immediately prior to 
adaptation to TGFβR2i-1 readily responded, whereas 
another line of the parental MCF7 line grown in another 
laboratory exhibited growth inhibition (Figure 5D). At 
the molecular level we found elements of an estrogen 
response common between iHBECERpos and MCF7, but 
more importantly also subtle differences. Based on an RT-
qPCR time course of key estrogen-regulated genes, we 
found that a six hour-exposure to estrogen was the optimal 
time point for further RNA-Seq expression analysis of 
the two cell lines (Figure 5E). To identify differentially 
expressed genes regulated by estrogen, a robust 
bioinformatics method, NOISeq [25], was performed. 
Among statistically significant most-up-regulated genes 
in iHBECERpos (fold difference >2 and probability >0.7), 
we found well known estrogen-regulated genes, such as 
Figure 1: Infinite lifespan of hTERT/shp16 transduced iHBECERpos cells. Population doublings as a function of time in culture 
of iHBECERpos cells (passage 28-36, circles) and MCF7 cells (passage 309-319, squares) upon switch to TGFβR2i-1. Both cell lines have 
infinite lifespans under these conditions. MCF7 cannot grow in TGFβR2i (open diamonds, individual time points), but readily adapt to 
TGFβR2i-1 (closed diamonds) and stop growing and cannot be passed more than twice when switched back to TGFβR2i (open squares).
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Figure 2: Characterization of hTERT/shp16 transduced iHBECERpos cells. Immunofluorescence staining of iHBECERpos and 
MCF7 cells with key breast lineage markers luminal keratin K19, K8 and MUC1 and myoepithelial p63 and K14 (green). Nuclei are 
counterstained with DAPI (blue). Note the striking similarity with respect to epitheloid morphology and luminal profile. Bar: 50μm.
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IGFBP4 and GREB1 (Figure 5F) [26, 27]. These genes 
have physiological roles in steroid hormone responsive 
tissues, and were also upregulated in the present MCF7 
cells as well as in an alternative dataset on the MCF7 
estrogen response (Figure 5F) [28]. Three genes, GATA4, 
CXCL12 and MYB, were significantly upregulated in 
MCF7, while changes in expression were not observed 
in iHBECERpos. These are all estrogen regulated genes 
that have been implicated in breast cancer evolution 
[29–31]. Moreover, a cytokine binding receptor, IL1R1, 
found by others [28] to be significantly down-regulated in 
MCF7 was also downregulated in MCF7 here (1.5 fold), 
but was significantly upregulated in iHBECERpos. These 
findings implicate that availability of normal breast ERpos 
cells may reveal important endocrinological differences 
between normal and cancer.
A relevant stromal microenvironment segregates 
proliferating and ER-expressing normal cells
These differences led us to speculate whether 
iHBECERpos and MCF7 would also recapitulate the 
widely appreciated dissociation between ER expression 
and cell proliferation in the normal breast as opposed 
to its disruption in cancer [32]. For this purpose we 
plated primary EpCAMhigh/CD271low/CD166high/CD117low 
Figure 3: iHBECERpos cells exhibit an expression profile reminiscent of luminal progenitors. Expression profiles of twenty 
highest ranking markers in each group of mammary stem cells/bipotent cells (MaSC/BiPs), luminal progenitors (pLs), and mature luminal 
cells (mLs), respectively, according to the Lim classification [23] as compared to gene expression profiles of iHBECERpos and MCF7 by 
RNA-Seq. Twelve, twelve and fourteen genes in each group, respectively, were informative. Whereas mature luminal genes are highly 
expressed in MCF7, luminal progenitor genes are pronounced in iHBECERpos cells. X-axis indicates FPKM values, as calculated by gene 
expression levels (Fragments Per Kilobase Of Exon Per Million Fragments Mapped; FPKM in iHBECERpos, red, and MCF7, blue), and 
Y-axis indicates each subpopulation of genes present in our RNA-Seq dataset.
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ER-positive cells, iHBECERpos, and MCF7 on human 
breast fibroblasts [33]. Whereas iHBECERpos under 
these conditions behaved like EpCAMhigh/CD271low/
CD166high/CD117low primary cells and readily formed 
correctly polarized K19+/K14- acini in the presence 
of TGFβR inhibitors, and in the presence of estrogen, 
branching structures, MCF7 formed tumor-like nests 
of cells without appreciable polarization (Figure 6). In 
contrast to normal ERpos cells, which do not grow [22] 
or undergo morphogenesis on fibroblast feeders [33] in 
the absence of TGFβR inhibitors, growth of MCF7 was 
inhibited by TGFβR inhibitors. More importantly, we 
found that in iHBECERpos for the major part segregated 
ERpos cells from Ki-67-positive cells while in MCF7 
cells staining frequently overlapped (Ki-67 and ER co-
expression in 6.5 % +/- 2.6 versus 32.3 % +/-5.5 of the 
cells, respectively, Figure 6). Based on these findings, 
we conclude that together, iHBECERpos and MCF7 are 
well suited for lineage aligned comparisons between 
normal and cancer within the context of human breast 
cancer.
Figure 4: iHBECERpos cells are normal-like by the rBM assay. Phase contrast micrographs of iHBECERpos (left column) and MCF7 
cells (right column) on tissue culture plastic (upper panel) and in 3D rBM gels at day 8 (middle panel). Whereas both iHBECERpos and MCF7 
cells in monolayer culture are typically epitheloid, inside rBM gels iHBECERpos are capable of forming acinus-like spheres with a central 
lumen while MCF7 cells grow as solid irregular colonies. Cryostat sections of rBM gels (lower panel) stained with MUC1 (green), K19 
(red) and nucleus counterstain (blue) show that iHBECERpos are correctly polarized while MCF7 fail to polarize. Bar: 50μm.
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Figure 5: iHBECERpos and MCF7 cells respond differently to TGFβR inhibitors and estrogen. A. Immunoperoxidase 
staining of iHBECERpos (left column) and MCF7 (right column) stained with ER (upper panel) and PR (lower panel) and counterstained with 
hematoxylin. B. Western blotting of proteins extracted from iHBECERpos cells or MCF7 at day 6 upon omission of TGFβR inhibitors (-) or in 
continuous TGFβR2i-1 (+), incubated with antibodies recognizing ERα (upper panel), phosphorylated SMAD2 (pSMAD2, second panel), 
SMAD2/3 (third panel) and loading control β-actin (lower panel). While iHBECERpos cells upregulate pSMAD2 and lose ER expression 
upon omission of TGFβR inhibitors, MCF7 upregulate pSMAD2 without concurrent regulation of ER. C. Quantification of ER (black 
bars) and PR (grey bars) expression by immunoperoxidase staining of iHBECERpos (left panel) and MCF7 cells (right panel) cultured with 
vehicle or estrogen (E2) shows that ER is downregulated in both lines upon exposure to estrogen, and PR is significantly upregulated in 
iHBECERpos (asterisks indicate significance by Student´s T-test, p<0.05). D. Cell number after 7 days in quaduplicate cultures of iHBECERpos 
and MCF7 plated at 6,000 and 4,000 cells/cm2, respectively, and exposed to vehicle (light grey bars), to estrogen (10-8M, dark grey bars) 
without or with estrogen receptor antagonist (10-8M and 10-9M ICI 182,780, respectively, black bars). Two different lines of the MCF7 
parental line plated at 4,000 cells/cm2 in triplicate grown in standard medium exposed to estrogen (10-8M) without or with ICI 182,780 
(10-7M) demonstrate growth stimulation in the immediate origin of the TGFβR2i-1-adapted subline (MCF7p1) and inhibition in response 
to estrogen in a line grown in another laboratory (MCF7p2). Bars indicate mean and standard deviation and technical variation. Asterisks 
indicate significance (p< 0.05; Student´s T-test, two-tailed). 
(Continued )
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Figure 5: (Continued ) E. RT-qPCR of ESR1, PgR and ELF5 gene expression levels in iHBECERpos (left panel) and MCF7 (right 
panel) upon exposure to estrogen for 1h, 3h, 6h, 12h, and 24h, respectively. Y-axis indicates relative normalized gene expression levels 
compared to vehicle-treated samples in log
2
-scale. F. Heat map of fold difference assessed by RNA-Seq in expression of genes regulated 
in iHBECERpos (left), MCF7 (middle) and a previously published dataset on MCF7 grown in standard medium (* right; [28]). Similarity in 
estrogen-regulated gene expression profile between iHBECERpos and MCF7 includes IGFBP4, GREB1, FMN1, CISH, TFF1, PGR, PDZK1, 
and differences include the genes GATA4, CXCL12 and MYB, which are upregulated in MCF7 only, and IL1R1, which is upregulated in 
iHBECERpos, but downregulated in MCF7. Color key indicates fold difference in log
2
 scale.
DISCUSSION
By far the majority of cellular turnover in the normal 
human breast takes place in the luminal epithelial lineage, 
and with rare exceptions breast cancer – including the 
so-called basal-like – originates from this lineage [23]. 
Paradoxically, attempts to model breast homeostasis 
in cell based assays have been severely confounded by 
overgrowth of another major lineage, i.e. the myoepithelial 
[16]. We describe here an established cell line iHBECERpos 
which remain luminal-like in TGFβR2i-1 without the 
inherent propensity to drift towards the myoepithelial 
lineage and thus lending itself to more sensible 
comparisons with breast cancer. A fundamental property 
that distinguishes this cell line from previous human 
breast cell lines of non-malignant origin is the expression 
of functional sex hormone receptors. We here present 
evidence that the cell line represents a luminal progenitor 
and that it may serve to unravel the enigmatic division 
of labor between steroid hormone expressing cells and 
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Figure 6: A characteristic switch in ER expression and growth between normal and cancer is retained in organoid 
culture. Multicolor imaging of iHBECERpos (left column) and MCF7 (right column) plated on a feeder of human fibroblasts and stained 
after two weeks for MUC1 (green) and keratin K19 (red) on a background of blue nuclei (DAPI) in BBMYAB with TGFβR inhibitors 
(upper panel) and in the presence of estrogen (middle panel). Whereas iHBECERpos cells exhibit outside-in polarization and mostly form 
acini in the absence of estrogen and more elaborate branching morphogenesis in the presence of estrogen, MCF7 cells under both conditions 
form irregular colonies without signs of tubular morphogenesis. Dual color imaging of iHBECERpos (left column) and MCF (right column) 
in organoid culture stained for ER (green) and Ki67 (red) (lower panel) show preferential segregation into separate compartments in 
iHBECERpos as opposed to more frequent overlap in MCF7 (orange nuclei).
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proliferating cells in the normal breast -perhaps being 
extrapolatable to all endocrine receptor expressing tissues 
as opposed to cancer.
Circulating estrogen induces the expression of PR 
in ER expressing cells and together with progesterone 
it elicits growth of neighboring luminal progenitors in 
a paracrine manner ([32];for review see [34]). We find 
that iHBECERpos respond to estrogen by an upregulation 
of PR and accelerated growth in monolayer culture. With 
respect to downregulation of ER expression iHBECERpos 
responds very much like the malignant MCF7 cells. 
However, specifically in MCF7 cells, response to estrogen 
does not necessarily concur with accelerated growth. In 
other words, the growth response to estrogen between 
normal and cancer is not identical. We note that others 
have reported that MCF7 cells, somewhat dependent 
on the source of cells, do not respond with growth to 
added estrogen [35]. In vivo ER- positive breast cancer 
cells are characterized by growth concomitant with ER 
expression [1, 32]. Our observations indicate that in 
rBM growth of iHBECERpos as opposed to MCF7 cells is 
regulated in a manner similar to normal breast epithelial 
cells [24]. However, in spite of recapitulation of acinus-
like morphology, the rBM assay does not suffice to 
maintain ER expression for extended periods. Therefore, 
iHBECERpos serves to dissect both similarities and 
dissimilarities between normal and cancer.
One of the longstanding puzzles in breast cancer 
is the apparent dissociation between growth and ER 
expression in the normal breast and its disruption in cancer 
[32]. Our findings here of stromal cells as instrumental in 
providing the necessary microenvironment for maintaining 
ER expression and segregating ER expressing and growing 
cells into distinct compartments in iHBECERpos opens for 
a more detailed analysis of the mechanism behind this 
disruption. One mechanism which is known to function 
differently in normal versus cancer is TGFβ signaling 
(for review see [36]). Whereas it in normal breast induces 
quiescence, in cancer it induces epithelial to mesenchymal 
transition (EMT). Research by ourselves and others has 
shown that TGFβ signaling serves to control growth and 
ER expression of normal mammary epithelial cells [22, 
37]. Our findings here that MCF7 exhibits a relatively 
modest expression of pSMAD2 and fails to respond to 
TGFβR2i by appreciably modulating ER expression may 
help explain the disrupted association between growth and 
ER expression in cancer.
One of the four big questions in the field of breast 
cancer as recently highlighted in a Nature editorial 
is: “What are the risk factors for the disease?” [38]. It 
was reasoned that knowledge about susceptibility will 
illuminate the root causes of this disease and lead to new 
approaches for prevention and treatment. Accordingly, our 
findings of a switch in the ER response to TGFβ inhibitors 
between normal and cancer offers an avenue for a cell 
based screening of more selective estrogen receptor down 
regulators (SERDs) in breast cancer chemoprevention.
MATERIALS AND METHODS
Ethics statement
Normal breast biopsies of which some were included 
in previous work [22] were collected with consent from 
women undergoing reduction mammoplasty for cosmetic 
reasons. The storage and use of human material has been 
approved by the Regional Scientific Ethical Committees 
(Region Hovedstaden, H-2-2011-052) and the Danish Data 
Protection Agency (2011-41-6722).
Culture of primary cells and cell lines
EpCAMhigh/CD271low/CD166high/CD117low ER-
positive cells were purified from normal breast as 
previously described [22]. Cells transduced with hTERT/
shp16 in early passage [22] were cultured in Primaria 
(#3813, Becton Dickenson) in the presence of TGFβR2i 
medium (Dulbecco´s modified Eagle´s medium (DMEM, 
high glucose, no calcium, Life Technologies):Ham´s 
F12 Nutrient Mixture (F12, Life Technologies), 3:1 
v/v), 0.5 μg/ml hydrocortisone, 5 μg/ml insulin, 10 ng/
ml cholera toxin (Sigma-Aldrich), 10 ng/ml epidermal 
growth factor (Peprotech), 1.8 x10-4 M adenine (Sigma 
Aldrich), 10 μM Y-27632 (Axon Medchem) and 5% 
fetal bovine serum (Sigma Aldrich), with the addition of 
the selective inhibitor of TGF-β type I receptor activin 
receptor-like kinase ALK5, ALK4 and ALK7, SB431542 
(10 μM, Axon 1661, Axon Medchem) and an inhibitor 
of autophosphorylation of ALK-5, RepSox (25-50μM, 
R0158, Sigma Aldrich) [22]). To restrict the luminal 
phenotype, in 6th and again in 11th passage, CD146high 
cells were purified by FACS (P1H12 1:500, ab24577, 
Abcam, as primary antibody and goat anti-mouse IgG1 
Alexa Flour 647, 1:500, Life Technologies as secondary), 
and in 22nd passage CD146high/CD117high cells (CD146, 
1:20, BD Biosciences followed by IgG1 Alexa Flour 647 
and CD117, 104D2-PE (1:20)) were sorted. For some 
experiments cells resorted as EpCAM+/CD117high in 
passage 35 were employed. For dead cell discrimination 
cells were incubated with either propidium iodide (1μg/ml, 
Invitrogen) or Fixable Viability Dye eFluor 780 (1:1000, 
Affymetrix) prior to FACS (FACSAria I and II, BD 
Biosciences). iHBECERpos cells were adapted to grow in 
modified TGFβR2i medium, TGFβR2i-1, i.e. substitution 
of epidermal growth factor for amphiregulin (5 nM, R&D 
Systems or Peprotech) and omission of hydrocortisone and 
cholera toxin, in passage 27, 29 or 30. To ensure that the 
cellular origin, EpCAMhigh/CD271low/CD166high/CD117low 
cells, could also grow and express the luminal phenotype 
in TGFβR2i-1, primary cells expanded in TGFβR2i were 
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passaged with TGFβR2i-1 at a density of 12,000 cells/cm2, 
and ER expression was analyzed up to passage four by 
immunocytochemistry.
MCF7 cells were obtained and cultured as 
previously described [39]. The cells were adapted to grow 
on Primaria in TGFβR2i-1 in passage 309. To demonstrate 
short-term response to TGFβR2i the parental line was 
seeded in passage 283 at 5,000 cells/cm2, counted at day 
7, 14 and 21, and the adapted cells grown in TGFβR2i-1 
for 37 passages were switched back to TGFβR2i, counted 
and passed at day 12 and counted at day 26.
Registration of population doublings was started 
immediately upon switching iHBECERpos and MCF7 to 
TGFβR2i-1 and population doublings were calculated as 
n= 3.32(log UCY-logI) +X, where n= population doubling, 
UCY = cell yield, I= inoculum and X= population doubling 
rate of inoculum.
Normal intralobular fibroblasts were sorted by 
FACS as CD105high/CD26low and cultured as described 
[33].
Reconstituted basement membrane (rBM) 
cultures
To recapitulate in situ morphology 400,000 
iHBECERpos or 200,000 MCF7 cells were embedded in 
300 μl ice cold MatrigelR Matrix (growth factor reduced 
and phenol red free, 356231, Corning), seeded in a 24-
well (Nunc) and solidified at 37°C before addition of 
1 ml CDM3 [40] without HEPES and trace element 
mix, in which epidermal growth factor was replaced by 
amphiregulin (5 nM) and supplemented with TGFβR 
inhibitors. Morphology was observed and photographed 
by phase contrast microscopy [24]. Colony formation in 
two times technical triplicates was quantified by phase 
contrast microscopy at 20x magnification using an ocular 
grid, 300 colonies per gel. Gels were frozen in n-hexane 
cooled in dry ice and prepared for immunostaining after 
14 days.
Co-culture
EpCAMhigh/CD271low/CD166high/CD117low primary 
cells, iHBECERpos or MCF7 cells were plated at a density 
of 5,600 cells/cm2 on confluent cultures of normal 
intralobular CD105high/CD26low fibroblasts in modified 
breastoid base medium without HEPES [41] (Dulbecco's 
Modified Eagle Medium/Nutrient Mixture F-12, 1:1, Life 
Technologies), 1 μg/ml hydrocortisone, 9 μg/ml insulin, 5 
μg/ml transferrin (Sigma-Aldrich), 5.2 ng/ml Na-Selenite 
(BD Industries), 100 μM ethanolamine (Sigma-Aldrich), 
20 ng/ml basic fibroblast growth factor (PeproTech), 5 nM 
amphiregulin, with the addition of 10 μM Y-27632, 1.8 
x10-4 M adenine and serum replacement B27 (20μl/ml, 
Life Technologies) [22] (BBMYAB, [33]). The day after 
plating, SB431542 and RepSox were added. To assess the 
influence of estrogen, β-estradiol (10-8M, E2758, Sigma-
Aldrich) or vehicle (ethanol) was added. Cultures were 
observed daily by phase contrast microscopy.
Immunocytochemistry
Cell cultures and 7 μm sections of gels were prepared 
for immunocytochemical staining essentially as described 
and the standard fixation protocol is methanol for 5 min 
at -20°C [21, 42, 43]. Of note, however, staining for ER 
requires a special fixation protocol. In brief, cultures were 
rinsed in phosphate buffered saline (PBS), pH 7.4 prior 
to fixation for 5 min at RT in 3.7% formaldehyde, two 
rinses in PBS, fixation in methanol:acetone 1:1 v/v for 5 
min at -20°C, two rinses in PBS, permeabilization in 0.1% 
Triton X-100 in PBS, twice for 7 min, rinse in PBS and 
kept wet prior to application of blocking buffer. To verify 
the luminal phenotype cells were stained for K19 (BA16, 
1:25, Abcam), K8 (TS1, 1:25, Novocastra) and sialomucin 
MUC1 (115D8, 1:10, Monosan) and to exclude a basal 
phenotype for K14 (LL002, 1:25, NeoMarkers) and p63 
(7JUL, 1:10, Novocastra) for 90 minutes, washed three 
times in 10% normal goat serum in PBS prior to 30 min 
incubation with AF488-conjugated secondary antibodies.
To assess polarization in rBM, sections of gels were 
stained with primary antibodies against sialomucin (1:10) 
and K19 (1:50, Abcam or 1:800, Genway) for 60 min 
followed by 60 min with secondary antibodies. Staining 
for ER was performed using peroxidase (SP1 ready-to-
use, Labvision) or fluorescence (1D5 1:25, Dako M7047)).
Co-cultures were double-stained with combinations 
of K19 (BA16 1:50, Abcam and 1:800, Genway, anti-
IgG1 AF568 1:500), K14 (LL002 1:25, anti-IgG3 AF488 
1:500), ER (1D5 1:25, anti-IgG1 AF568, 1:500), MUC1 
(115D8 1:10, anti- IgG2b AF488, 1:500) and Ki67 (SP6 
rabbit monoclonal, 1:25, RM 9106-S, Thermo Scientific, 
goat anti-rabbit IgG AF488, 1:500) at day 13-14.
Nuclei were stained with 4, 6-diamidino-2-
phenylindole (DAPI, Life Technologies) and sections 
or cultures were mounted with ProLong Gold antifade 
reagent prior to confocal microscopy (Zeiss, LSM700). 
The degree of overlap between ER and Ki-67 was assessed 
by counting 3x200 cells in technical triplicate of each 
culture on randomly collected microscopic images.
Response to estrogen
The response to estrogen and an estrogen receptor 
antagonist was assessed by plating four sets of 6,000 
iHBECERpos cells/cm2 or 4,000 MCF7 cells/cm2 and 
exposing them to estrogen (10-8M, β-estradiol, E2758, 
Sigma-Aldrich) with or without estrogen receptor 
antagonist (10-8M and 10-9M Fulvestrant, ICI 182,780, 
Sigma-Aldrich, respectively) as compared to vehicle 
(ethanol) for seven days prior to trypsination and counting 
(CASY cell counter). An additional set of cultures was 
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stained for ER and PR by peroxidase and counterstained 
with hematoxylin. To test the response to estrogen with or 
without ICI 182,780 (10-7M) in the parental MCF7 line in 
standard medium, lines in passage 287 and 312, cultured 
in separate laboratories since passage 240 were employed. 
To quantify for ER and PR expression upon estrogen 
stimulation 12,000 iHBECERpos cells/cm2 in passage 35 
(adapted to TGFβR2i-1 in passage 29) or 5,000 MCF7 
cells/cm2 in passage 328 (adapted in passage 309) were 
cultured with vehicle or estrogen (10-8M) for 8 days and 
stained by peroxidase, counterstained with hematoxylin 
and quantified (3x100 cells) [22].
RNA extraction, real-time quantitative (RT-q)
PCR and transcriptome analysis
Prior to comparison of transcriptional profiles in 
response to estrogen, iHBECERpos cells and MCF7 cells 
were cultured in TGFβR2i -1 for a total of 32 and 45 days, 
respectively. iHBECERpos cells in passage 33 were plated 
at a density of 24,000 cells/cm2 and MCF7 in passage 316 
at a density of 4,000 cells/cm2. After six days of culture, 
cells were exposed to estrogen (10-8M) or vehicle (ethanol) 
for 1, 3, 6, 12 and 24 hours. Total RNA was extracted 
and reverse transcribed and RT- qPCR was performed as 
described [22].
For transcriptome analysis each group with or 
without estrogen for 6h was run in triplicate using RNA-
Seq technology [44]. Sequencing and bioinformatics 
analysis was conducted by Beijing Genomics Institute 
(BGI), Hongkong. In short, Oligo dT magnetic beads 
were used to select mRNAs with poly A tails or DNA 
probes were used to hybridize rRNAs to get rid of 
rRNAs. Selected mRNAs were fragmented and reversely 
transcribed to double-stranded cDNA (dscDNA) by N6 
random primers. Ends of dscDNAs in turn were repaired 
with phosphate at 5’ end and A at 3’ end in order to ligate 
adaptors with stickiness T at 3’ end to the dscDNAs 
which were subjected to amplification. In order to prepare 
products for sequencing, called a library, the PCR products 
were denatured and single stranded PCR products were 
cyclized by splint oIigos with DNA ligase. The prepared 
library was then sequenced using BGISEQ-500 platform 
generating 23,958,189 raw sequencing reads. Clean 
reads of 23,950,466 after filtering low quality was 
mapped to reference using HISAT/Bowtie2 tool with 
the mean mapping rate of 79%. Gene quantification was 
measured by FPKM calculated based on the expectation 
maximization algorithm called RSEM ([45].
For subcellular classification, transcribed genes 
found here without estrogen stimulation in iHBECERpos 
and MCF7, respectively, were compared to a previously 
published dataset of human breast lineage gene expression 
profiles [23]. Differentially expressed gene lists of the 
human breast lineages defined by CD49f and EpCAM 
status based on microarray analysis was obtained from 
supplementary tables 5, 6 and 7 in Lim et al. [23]. Among 
them, the most highly expressed 20 genes in each lineage: 
MaSC, luminal progenitor (pLs), or mature luminal (mLs) 
were selected and searched for their presence in our RNA-
Seq data. Using gene expression levels calculated by 
FPKM from the clean data with coverage>0 in triplicate, 
12 genes in MaSc, 14 genes in pLs and 12 genes in mLs 
were present in our sequencing data.
To identify differentially expressed genes regulated 
by estrogen, the NOIseq method [25] was performed, 
using the filtering condition of the probability higher than 
0.7 with fold difference more than 2. When FPKM value 
was not available (coverage=0), the value was treated as 
0.01 as the default FPKM. Among statistically significant 
differentially expressed genes, we selected a repertoire 
of genes that were upregulated either in iHBECERpos or 
in MCF7. Differentially regulated genes in MCF7 were 
further validated by comparing to a previously published 
dataset on estrogen-regulated genes in MCF7 [28].
Western blotting
For Western blotting protein was extracted at day 
6 from iHBECERpos cells in passage 36 seeded at 18,000 
cells/cm2 and MCF7 cells in passage 325 seeded at 4,000 
cells/cm2 and cultured with or without TGFβR inhibitors. 
25 μg of protein was loaded in each lane and Western 
blotting was performed as previously described [22].
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